The pope's salary: How does the pontiff get paid?
The leader of the Roman Catholic Church does not get paid what many consider a traditional salary. Instead, the Vatican provides for the pontiff's needs, from housing, food, transportation and other expenses in the form of stipends and allowances.
The Vatican, referred to as "the world's smallest country," is sustained by "an economy that relies on a combination of donations, private enterprises, and investments to generate revenue," according to Investopedia.
Pope Francis declined any sort of salary when he took office in 2013, The Economic Times reported back in February, adding that the pontiff at the time had a net worth of "around $16 million, which includes various assets provided to him as the pope."
The Vatican's financial situation has been in peril for years, with its annual operating deficit growing to over $90 million in 2023, according to reports. In November, Pope Francis warned that the Vatican's pension fund — which provides pensions to employees of the Holy See and Vatican City State — has been facing a "severe prospective imbalance" that "tends to grow over time in the absence of interventions," according to the Vatican News.
LIVE UPDATES: 'EXTRA OMNES' ORDER GIVEN, OFFICIALLY BEGINNING PAPAL CONCLAVE
The governing body of the Vatican, also known as the Holy See, doesn't provide exact numbers regarding its finances. However, the Central Intelligence Agency's World Factbook estimated its revenues and expenditures in 2013 notched $315 million and $348 million, respectively.
It generates this money through various avenues. According to the Michigan Journal of Economics, the Holy See generates some of its revenue through Peter's Pence, which is a term that describes donations collected from Catholics around the world and given to the Pope on an annual basis. This accounts for $27 million each year, with the largest contributions deriving from the United States, Germany and Italy, according to American Magazine.
WHAT IS THE PAPAL CONCLAVE: INSIDE THE ANCIENT PROCESS OF CHOOSING THE NEXT POPE
CLICK HERE TO GET THE FOX NEWS APP
Fox News Digital reached out to the Vatican and United States Conference of Catholic Bishops for more information about how the pope gets paid, but did not immediately hear back.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
31 minutes ago
- Yahoo
If EPS Growth Is Important To You, Johnson Matthey (LON:JMAT) Presents An Opportunity
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to investors, even if it currently lacks a track record of revenue and profit. Sometimes these stories can cloud the minds of investors, leading them to invest with their emotions rather than on the merit of good company fundamentals. A loss-making company is yet to prove itself with profit, and eventually the inflow of external capital may dry up. If this kind of company isn't your style, you like companies that generate revenue, and even earn profits, then you may well be interested in Johnson Matthey (LON:JMAT). Now this is not to say that the company presents the best investment opportunity around, but profitability is a key component to success in business. This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality. Generally, companies experiencing growth in earnings per share (EPS) should see similar trends in share price. Therefore, there are plenty of investors who like to buy shares in companies that are growing EPS. Recognition must be given to the that Johnson Matthey has grown EPS by 54% per year, over the last three years. Growth that fast may well be fleeting, but it should be more than enough to pique the interest of the wary stock pickers. Top-line growth is a great indicator that growth is sustainable, and combined with a high earnings before interest and taxation (EBIT) margin, it's a great way for a company to maintain a competitive advantage in the market. Johnson Matthey's EBIT margins are flat but, worryingly, its revenue is actually down. Suffice it to say that is not a great sign of growth. The chart below shows how the company's bottom and top lines have progressed over time. Click on the chart to see the exact numbers. View our latest analysis for Johnson Matthey Fortunately, we've got access to analyst forecasts of Johnson Matthey's future profits. You can do your own forecasts without looking, or you can take a peek at what the professionals are predicting. Investors are always searching for a vote of confidence in the companies they hold and insider buying is one of the key indicators for optimism on the market. This view is based on the possibility that stock purchases signal bullishness on behalf of the buyer. Of course, we can never be sure what insiders are thinking, we can only judge their actions. Shareholders in Johnson Matthey will be more than happy to see insiders committing themselves to the company, spending UK£234k on shares in just twelve months. This, combined with the lack of sales from insiders, should be a great signal for shareholders in what's to come. We also note that it was the CEO & Director, Liam Condon, who made the biggest single acquisition, paying UK£134k for shares at about UK£13.42 each. Johnson Matthey's earnings per share have been soaring, with growth rates sky high. Growth-minded people will be intrigued by the incredible movement in EPS growth. And indeed, it could be a sign that the business is at an inflection point. If this these factors intrigue you, then an addition of Johnson Matthey to your watchlist won't go amiss. You still need to take note of risks, for example - Johnson Matthey has 4 warning signs (and 1 which is a bit concerning) we think you should know about. Keen growth investors love to see insider activity. Thankfully, Johnson Matthey isn't the only one. You can see a a curated list of British companies which have exhibited consistent growth accompanied by high insider ownership. Please note the insider transactions discussed in this article refer to reportable transactions in the relevant jurisdiction. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
34 minutes ago
- Yahoo
H.C. Wainwright Maintains a Buy Rating on Agios Pharmaceuticals (AGIO), Reduces PT
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) is one of the 10 Best Small-Cap Growth Stocks to Buy According to Analysts. On June 9, Analyst Emily Bodnar of H.C. Wainwright maintained a Buy rating on Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) and reduced the price target from $61 to $56. The reiteration comes after the company announced its commercial and distribution agreement with Avanzanite for its drug Pyrukynd in Europe, Switzerland, and the UK. The analyst said that the recent agreement of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) with Avanzanite mirrors its previously successful collaboration in the Gulf region. The agreement will enable the company to concentrate on the US market while leveraging Avanzanite's expertise in European rare disease markets. Moreover, Pyrukynd has already been approved for pyruvate kinase deficiency and is expected to receive FDA approval for thalassemia and potentially EMA approval in 2026. A technician in a lab looks off into the distance, showcasing the research taking place at Agios Pharmaceuticals. Analyst Emily Bodnar lowered the price target due to the agreement's revenue split which initially benefits Avanzanite. However, Bodnar views it as a capital-efficient way to accelerate Agios' entry and revenue growth in Europe. Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) is a biopharmaceutical company specializing in developing innovative therapies for patients with rare diseases. Its main product, Pyrukynd (mitapivat), is the first disease-modifying treatment for adults with pyruvate kinase deficiency, a form of hemolytic anemia. While we acknowledge the potential of AGIO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Sign in to access your portfolio
Yahoo
an hour ago
- Yahoo
Institutional investors in ING Groep N.V. (AMS:INGA) see €1.8b decrease in market cap last week, although long-term gains have benefitted them.
Institutions' substantial holdings in ING Groep implies that they have significant influence over the company's share price 41% of the business is held by the top 25 shareholders Insiders have been selling lately This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality. To get a sense of who is truly in control of ING Groep N.V. (AMS:INGA), it is important to understand the ownership structure of the business. And the group that holds the biggest piece of the pie are institutions with 57% ownership. In other words, the group stands to gain the most (or lose the most) from their investment into the company. Losing money on investments is something no shareholder enjoys, least of all institutional investors who saw their holdings value drop by 3.2% last week. Still, the 27% one-year gains may have helped mitigate their overall losses. They should, however, be mindful of further losses in the future. Let's delve deeper into each type of owner of ING Groep, beginning with the chart below. View our latest analysis for ING Groep Institutional investors commonly compare their own returns to the returns of a commonly followed index. So they generally do consider buying larger companies that are included in the relevant benchmark index. As you can see, institutional investors have a fair amount of stake in ING Groep. This can indicate that the company has a certain degree of credibility in the investment community. However, it is best to be wary of relying on the supposed validation that comes with institutional investors. They too, get it wrong sometimes. It is not uncommon to see a big share price drop if two large institutional investors try to sell out of a stock at the same time. So it is worth checking the past earnings trajectory of ING Groep, (below). Of course, keep in mind that there are other factors to consider, too. Investors should note that institutions actually own more than half the company, so they can collectively wield significant power. Hedge funds don't have many shares in ING Groep. Looking at our data, we can see that the largest shareholder is Capital Research and Management Company with 7.2% of shares outstanding. In comparison, the second and third largest shareholders hold about 6.3% and 4.2% of the stock. On studying our ownership data, we found that 25 of the top shareholders collectively own less than 50% of the share register, implying that no single individual has a majority interest. Researching institutional ownership is a good way to gauge and filter a stock's expected performance. The same can be achieved by studying analyst sentiments. Quite a few analysts cover the stock, so you could look into forecast growth quite easily. While the precise definition of an insider can be subjective, almost everyone considers board members to be insiders. The company management answer to the board and the latter should represent the interests of shareholders. Notably, sometimes top-level managers are on the board themselves. Insider ownership is positive when it signals leadership are thinking like the true owners of the company. However, high insider ownership can also give immense power to a small group within the company. This can be negative in some circumstances. Our most recent data indicates that insiders own less than 1% of ING Groep N.V.. As it is a large company, we'd only expect insiders to own a small percentage of it. But it's worth noting that they own €3.3m worth of shares. It is always good to see at least some insider ownership, but it might be worth checking if those insiders have been selling. The general public-- including retail investors -- own 43% stake in the company, and hence can't easily be ignored. While this size of ownership may not be enough to sway a policy decision in their favour, they can still make a collective impact on company policies. I find it very interesting to look at who exactly owns a company. But to truly gain insight, we need to consider other information, too. To that end, you should be aware of the 1 warning sign we've spotted with ING Groep . If you are like me, you may want to think about whether this company will grow or shrink. Luckily, you can check this free report showing analyst forecasts for its future. NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
